<DOC>
	<DOCNO>NCT01467414</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial investigate pharmacodynamic ( effect investigate drug body ) property NN1250 ( insulin degludec ) Japanese subject type 2 diabetes .</brief_summary>
	<brief_title>A Trial Investigating Effect NN1250 Japanese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female Japanese subject age 2070 year ( inclusive ) Japanese passport holder Japaneseborn parent Type 2 diabetes mellitus ( diagnose clinically ) least 12 month Treated insulin least 3 month Body Mass Index ( BMI ) maximum 33.0 kg/m^2 Glycosylated haemoglobin A1c ( HbA1c ) maximum 10.0 % Fasting Cpeptide 1.0 nmol/L Use oral antidiabetic drug ( OADs ) and/or glucagon like peptide1 ( GLP1 ) receptor agonist ( exenatide , liraglutide ) within 3 month prior screen Subject donate blood plasma past month 500 mL within 3 month prior screen Not able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period Supine blood pressure screening ( rest 5 min ) minimum 180 mmHg systolic and/or minimum 100 mmHg diastolic</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>